Go Back

Biodesix Names Paul J Beresford, Formerly of Roche Diagnostics, as Vice President, Business Development and Stategic Marketing

Biodesix, Inc, announced today that Paul J. Beresford has joined the Company as Vice President, Business Development and Strategic Marketing, reporting directly to David Brunel, Chief Executive Officer. In this newly created position, Dr. Beresford will help drive all business development activities including the establishment of relationships with pharmaceutical and biotechnology to identify and develop companion diagnostics. Dr. Beresford will also be responsible for developing the company’s long term strategy, product development portfolio and overseeing the CLIA lab facilities. Prior to joining Biodesix, Paul held a number of senior management positions at Ventana Medical Systems and Roche Diagnostics including Vice President, General Manager of Translational Diagnostics.

“Paul provides Biodesix with instant credibility in the companion diagnostics space with his prior experience building relationships in biopharma at Ventana and Roche. Paul also brings a breadth of experience in tactical, product development and strategic marketing. We are looking forward to Paul joining the senior management team and helping to drive the long term growth and value of Biodesix.” Mr Brunel, CEO of Biodesix, said.

About Biodesix

Biodesix is a fully integrated molecular diagnostic company enabling personalized health care using mass spectrometry-based molecular profiling. Working with academic and biopharma collaborators, Biodesix uses its proprietary technology, ProTS® to discover and validate diagnostic tests that improve patient outcomes. Biodesix’ first product, VeriStrat, is commercially available for physicians to help guide their treatment of patients with non-small cell lung cancer. For more information on Biodesix, visit www.Biodesix.com.

This press release contains statements that are hereby identified as “forward-looking statements” for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the Company’s inability to further identify, develop and achieve commercial success for products and technologies; the risk that the Company’s financial resources will be insufficient to meet the Company’s business objectives; uncertainties relating to the regulatory approval process and changes in relationships with strategic partners. We disclaim any intent or obligation to update these forward-looking statements.

Topics: cancer diagnostics, personalized medicine, Press Releases, Strategic Marketing, lung cancer, marketing, molecular diagnostic, Non-Small Cell Lung Cancer, NSCLC, oncology